Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
The 15th Anniversary of Pharmaceutics—Advances and Future Trends in Drug...
share announcement

The 15th Anniversary of Pharmaceutics—Advances and Future Trends in Drug Delivery

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 2738

Special Issue Editors

Dr. Ortensia Ilaria Parisi

E-Mail Website
Guest Editor
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy
Interests: molecularly imprinted polymers; drug delivery; drug targeting; theranostics; functional polymers; stimuli-responsive polymers; biomaterials
Special Issues, Collections and Topics in MDPI journals
Dr. Marco Dattilo

E-Mail Website
Guest Editor
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy
Interests: molecularly imprinted polymers; drug delivery; drug targeting; theranostics; functional polymers; hydrogels; nanotechnology

Special Issue Information

Dear Colleagues,

The year 2023 marks the 15th anniversary of Pharmaceutics, and to celebrate this significant milestone, we aim to publish a Special Issue entitled “The 15th Anniversary of Pharmaceutics—Advances and Future Trends in Drug Delivery”.

Drug delivery can be defined as the process or method of administering a pharmaceutical compound to achieve a therapeutic effect both in humans or animals. The form in which a therapeutic agent is administered can exert an important impact on its efficacy and safety; thus, the use of suitable drug delivery systems (DDSs) can enhance both, leading to improved patient compliance.

In addition, the development of new drug molecules is expensive and time consuming, and DDSs represent new promising tools that can give a new life to old drugs by enabling controlled and/or targeted delivery, individualized therapy, real-time monitoring of therapeutic efficacy, improvements in stability, and the repositioning of exiting drugs for new therapeutic purposes.

In this Special Issue, original research articles and reviews are welcome.

We look forward to receiving your contributions.

Dr. Ortensia Ilaria Parisi
Dr. Marco Dattilo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug delivery
  • drug targeting
  • theranostics
  • nanotechnology
  • in vitro and in vivo drug delivery model development
  • drug repurposing
  • stimuli-responsive systems

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 4117 KiB  
Article
Engineered Hybrid Vesicles and Cellular Internalization in Mammary Cancer Cells
by So Yun Kim, Dagyeong Guk, Youngdo Jeong, Eunji Kim, Hansol Kim and Sung Tae Kim
Pharmaceutics 2024, 16(4), 440; https://doi.org/10.3390/pharmaceutics16040440 - 22 Mar 2024
Viewed by 1189
Abstract
Extracellular vesicles play an important role in intercellular communication, with the potential to serve as biomaterials for nanocarriers. Combining such extracellular vesicles and liposomes results in advanced drug delivery carriers. In this study, we attempted to fabricate hybrid vesicles using a membrane fusion [...] Read more.
Extracellular vesicles play an important role in intercellular communication, with the potential to serve as biomaterials for nanocarriers. Combining such extracellular vesicles and liposomes results in advanced drug delivery carriers. In this study, we attempted to fabricate hybrid vesicles using a membrane fusion method and incorporated an anticancer drug. As a result, we successfully prepared nanosized uniform hybrid vesicles and evaluated their physicochemical characteristics and intracellular uptake mechanisms via endocytosis in various cell lines. Compared to liposomes, the hybrid vesicles showed better physical properties and a relatively higher reduction in cell viability, which was presumably dependent on the specific cell type. These findings suggest that fusion-based hybrid vesicles offer a novel strategy for delivering therapeutic agents and provide insights into the types of extracellular vesicles that are useful in fabricating hybrid vesicles to develop an advanced drug delivery system. Full article
(This article belongs to the Special Issue The 15th Anniversary of Pharmaceutics—Advances and Future Trends in Drug Delivery)
►▼ Show Figures

Graphical abstract

11 pages, 4535 KiB  
Article
Human β-Defensin 23 as a Carrier for In Vitro and In Vivo Delivery of mRNA
by Kyoung-Ran Kim, Junghyun Kim, Seunghye Cho and Dae-Ro Ahn
Pharmaceutics 2023, 15(10), 2477; https://doi.org/10.3390/pharmaceutics15102477 - 17 Oct 2023
Viewed by 834
Abstract
The successful application of mRNA therapeutics hinges on the effective intracellular delivery of mRNA both in vitro and in vivo. However, this remains a formidable challenge due to the polyanionic nature, longitudinal shape, and low nuclease resistance of mRNA. In this study, we [...] Read more.
The successful application of mRNA therapeutics hinges on the effective intracellular delivery of mRNA both in vitro and in vivo. However, this remains a formidable challenge due to the polyanionic nature, longitudinal shape, and low nuclease resistance of mRNA. In this study, we introduce a novel mRNA delivery platform utilizing a human β-defensin peptide, hBD23. The positive charge of hBD23 allows it to form nanocomplexes with mRNA, facilitating cellular uptake and providing protection against serum nucleases. When optimized for peptide-to-mRNA (N/P) ratios, these hBD23/mRNA complexes demonstrated efficient cellular delivery and subsequent protein expression both in vitro and in vivo. Importantly, as hBD23 is human derived, the complexes exhibited minimal cytotoxicity and immunogenicity. Given its high biocompatibility and delivery efficiency, hBD23 represents a promising platform for the in vitro and in vivo delivery of mRNA. Full article
(This article belongs to the Special Issue The 15th Anniversary of Pharmaceutics—Advances and Future Trends in Drug Delivery)
►▼ Show Figures

Figure 1

Review

Jump to: Research

23 pages, 1127 KiB  
Review
Emerging Trends in Bilosomes as Therapeutic Drug Delivery Systems
by Hemlata Kaurav, Meenakshi Tripathi, Simran Deep Kaur, Amit Bansal, Deepak N. Kapoor and Sandeep Sheth
Pharmaceutics 2024, 16(6), 697; https://doi.org/10.3390/pharmaceutics16060697 - 23 May 2024
Viewed by 288
Abstract
In recent years, there has been a notable surge in the utilization of stabilized bile acid liposomes, chemical conjugates, complexes, mixed micelles, and other drug delivery systems derived from bile acids, often referred to as bilosomes. The molecular structure and interactions of these [...] Read more.
In recent years, there has been a notable surge in the utilization of stabilized bile acid liposomes, chemical conjugates, complexes, mixed micelles, and other drug delivery systems derived from bile acids, often referred to as bilosomes. The molecular structure and interactions of these amphiphilic compounds provide a distinctive and captivating subject for investigation. The enhanced stability of new generation bilosomes inside the gastrointestinal system results in the prevention of drug degradation and an improvement in mucosal penetration. These characteristics render bilosomes to be a prospective nanocarrier for pharmaceutical administration, prompting researchers to investigate their potential in other domains. This review paper discusses bilosomes that have emerged as a viable modality in the realm of drug delivery and have significant promise for use across several domains. Moreover, this underscores the need for additional investigation and advancement in order to comprehensively comprehend the prospective uses of bilosomes and their effectiveness in the field of pharmaceutical administration. This review study explores the current scholarly attention on bilosomes as prospective carriers for drug delivery. Therapeutic areas where bilosomes have shown outstanding performance in terms of drug delivery are outlined in the graphical abstract. Full article
(This article belongs to the Special Issue The 15th Anniversary of Pharmaceutics—Advances and Future Trends in Drug Delivery)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop